Filing Analysis
MAIA Biotechnology, Inc. announced the voting results from its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders re-elected two Class I directors and ratified the appointment of Grant Thornton LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
🚩 Red Flags
- There was significant shareholder dissent/withholding for director nominee Louie Ngar Yee, who received 8,796,832 'Withheld' votes compared to 16,658,677 'For' votes (approximately 34.6% withheld of votes cast).
📋 Key Facts
- The Annual Meeting was held on May 21, 2026, with 37,547,754 shares represented, constituting a 61.88% quorum of the 60,671,491 shares outstanding as of the March 23, 2026 record date.
- Class I directors Louie Ngar Yee and Steven Chaouki were re-elected to three-year terms expiring in 2029.
- The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified with 37,278,294 votes in favor.
MAIA Biotechnology has terminated its At-The-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC, effective seven business days after May 14, 2026. The company had recently raised approximately $5.68 million through the sale of 3.1 million shares under this facility.
📋 Key Facts
- Termination of the sales agreement dated February 14, 2024, with H.C. Wainwright & Co., LLC.
- Suspension of sales was effective as of May 14, 2026.
- Since the March 28, 2025 prospectus supplement, the company sold 3,116,012 shares for gross proceeds of $5,680,924.
- The March 2025 prospectus supplement had a total capacity of $11,200,000, meaning the company terminated the agreement with roughly half the capacity remaining.
MAIA Biotechnology announced the activation of its first U.S. clinical trial site for an ongoing international Phase 2 expansion trial. The study is evaluating a novel telomere-targeting treatment for patients with advanced non-small cell lung cancer (NSCLC).
📋 Key Facts
- Activated the first U.S. clinical trial site on April 16, 2026
- The trial is an ongoing international Phase 2 expansion study
- The treatment is a novel telomere-targeting therapy for advanced Non-Small Cell Lung Cancer (NSCLC)
- The announcement was made via a press release incorporated into the 8-K filing
MAIA Biotechnology announced that a recent $33 million capital raise is expected to fully fund its ongoing pivotal Phase 3 clinical trial of ateganosine, a novel telomere-targeting anticancer therapy. This capital infusion is intended to cover the costs of the trial through completion, addressing a major funding milestone for the company.
📋 Key Facts
- The company raised $33 million in a recent capital offering.
- Management expects these funds to fully fund the ongoing pivotal Phase 3 trial of ateganosine.
- Ateganosine is described as a novel telomere-targeting anticancer therapy.
- The filing was made under Item 8.01 (Other Events) on April 8, 2026.
MAIA Biotechnology approved one-time cash bonuses for its CEO and Head of Finance totaling $362,610. The bonuses were awarded specifically for their efforts regarding a recent capital raise.
🚩 Red Flags
- Cash bonuses awarded specifically for capital raising activities can be viewed as misaligned incentives, as management is being rewarded for dilutive events.
- Significant cash outflow for executive bonuses in a micro-cap biotech company which typically requires high cash reserves for R&D.
📋 Key Facts
- CEO Vlad Vitoc was awarded a one-time bonus of $312,610.
- Head of Finance Jeffrey Himmelreich was awarded a one-time bonus of $50,000.
- The bonuses were approved by the Board on March 27, 2026, and paid on March 31, 2026.
- The payments were made in consideration for efforts related to the company's recent capital raise.
MAIA Biotechnology announced positive clinical data from its ongoing Phase 2 trial for Non-Small Cell Lung Cancer (NSCLC). The company reported that eight patients in the study have achieved overall survival exceeding two years.
📋 Key Facts
- The report was filed on March 31, 2026, under Item 8.01 (Other Events).
- The clinical trial is an ongoing Phase 2 study targeting Non-Small Cell Lung Cancer (NSCLC).
- Eight patients in the trial have reached an overall survival milestone of more than 24 months.
- The data was released via a press release titled 'MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer'.
MAIA Biotechnology presented clinical data from its THIO-101 trial at the European Lung Cancer Congress (ELCC) 2026. The data highlights sustained therapeutic benefits in relapsed non-small cell lung cancer (NSCLC) patients treated with Ateganosine and Immune Checkpoint Inhibitors.
📋 Key Facts
- Presented a poster titled 'Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation' at the ELCC in Copenhagen on March 27, 2026.
- The clinical data is derived from the THIO-101 trial.
- The study focuses on relapsed NSCLC patients treated with Ateganosine (THIO) in combination with Immune Checkpoint Inhibitors (ICI).
- The poster was filed as Exhibit 99.1 and made available on the company's website.
MAIA Biotechnology entered into an underwriting agreement for a $30 million public offering of 20 million shares of common stock at $1.50 per share. The offering closed on March 4, 2026, with proceeds earmarked for clinical trials and general working capital.
🚩 Red Flags
- Potential for significant shareholder dilution given the 20,000,000 share count relative to micro-cap status.
- The 60-day lock-up period is relatively short for a public offering.
📋 Key Facts
- Offering of 20,000,000 shares of common stock at a public price of $1.50 per share.
- Gross proceeds of approximately $30.0 million before expenses.
- Underwriter Konik Capital Partners, LLC purchased shares at $1.425 per share (5% discount).
- Underwriter granted a 30-day option to purchase up to 3,000,000 additional shares to cover over-allotments.
- Company officers and directors entered into 60-day lock-up agreements.
- The offering closed on March 4, 2026.
MAIA Biotechnology issued a 2026 Letter to Shareholders and a press release providing updates on its clinical development pipeline. The communications highlight Phase 3 momentum and the company's potential within the $50 billion immunotherapy market.
📋 Key Facts
- Issued 2026 Letter to Shareholders on February 24, 2026
- Released press release titled 'MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market'
- Disclosed progress in the development pipeline and Phase 3 clinical momentum
- The filing includes the full text of the shareholder letter and press release as exhibits